This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

This product is a macrolide antibiotic, which has an inhibitory effect on Gram-positive bacteria such as Staphylococcus aureus, Streptococcus, and Pneumococcus, as well as some Gram-negative bacteria such as Haemophilus influenzae, Bordetella pertussis, Neisseria gonorrhoeae, Legionella pneumophila, and some anaerobic bacteria such as Bacteroides fragilis, Streptococcus peptostreptococcus, and Propionibacterium acnes. In addition, it also has an inhibitory effect on mycoplasma. In vivo, its antibacterial activity against some bacteria such as Staphylococcus aureus, Streptococcus, and Haemophilus influenzae is stronger than that of erythromycin. It produces an antibacterial effect by hindering the association of the 50S subunit of the nucleoprotein and inhibiting protein synthesis.

This product is a non-steroidal anti-inflammatory drug with anti-inflammatory, analgesic and antipyretic effects. Its mechanism of action is not yet fully understood, but it may be mainly related to the inhibition of prostaglandin synthesis, mediator release of leukocytes and oxidative reactions of polymorphonuclear leukocytes.